FAIRFIELD, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology, today announced the appointment of Brian Lenz, CPA, as its Chief Financial Officer. Mr. Lenz brings over 10 years of financial and operational management experience in addition to significant experience in capital raising and M&A activities.
"We are very pleased to have someone with Brian's broad financial and public markets experience join our team," said Scott Z. Fields, MD, President and Chief Medical Officer of Arno. "We look forward to working with him as we continue to grow and expand our operations."
Prior to joining Arno Therapeutics, Mr. Lenz was Chief Financial Officer and Treasurer of VioQuest Pharmaceuticals, Inc. since 2004, and prior to that served as the company's controller from 2003 to 2004. At VioQuest, Mr. Lenz was responsible for the financial and operational reporting, as well as capital raising and M&A activities. Prior to VioQuest, Mr. Lenz was a controller with Smiths Detection Group from 2000 to 2003. Before joining Smiths, Mr. Lenz was a senior auditor with KPMG, LLP from 1998 to 2000. Mr. Lenz holds a BS in Accounting from Rider University and received his MBA from Saint Joseph's University. He is a certified public accountant licensed in the State of New Jersey.
About Arno Therapeutics
Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company
that develops and commercializes innovative products for the treatment of
cancer patients. Arno's lead compound is AR-67, a novel, third-generation
camptothecin analogue in Phase I studies in patients with advanced solid
tumors that has demonstrated high potency and significantly improved
pharmacokinetic properties when compared with marketed second-generation
products in its class. Arno is also developing two pre-clinical compounds.
AR-12 is a potential first-in-class, orally available PDK
|SOURCE Arno Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved